具有补体系统抑制作用的中药活性成分研究进展
|
摘要
补体系统的异常激活可引起系统性红斑狼疮、类风湿性关节炎等多种免疫系统疾病。目前补体抑制剂的研发面临巨大挑战,然而从天然药物中提取分离的抗补体成分,如多糖、黄酮、萜类等具有很大的开发潜力,值得国内外学者进一步探究。本文对具有补体系统抑制作用的中药活性成分的研究概况进行综述,并分析天然活性成分抑制补体系统的应用前景,为今后进一步研究补体抑制剂提供科研思路和方法 。
The abnormal activation of the complement system can cause a variety of immune system diseases such as systemic lupus erythematosus and rheumatoid arthritis. At present, the development of complement inhibitors faces enormous challenges. However, the extraction of isolated anti-complement components from natural medicines, such as polysaccharides, flavonoids and terpenoids, has great potential for development and it is worthy of further exploration by domestic and foreign scholars. In this paper, the research status of active constituents of traditional Chinese medicine with inhibition of complement system is reviewed, and the application prospect of natural active ingredients inhibiting complement system is analyzed, so as to provide scientific research ideas and methods for further research on complement inhibitors.
The abnormal activation of the complement system can cause a variety of immune system diseases such as systemic lupus erythematosus and rheumatoid arthritis. At present, the development of complement inhibitors faces enormous challenges. However, the extraction of isolated anti-complement components from natural medicines, such as polysaccharides, flavonoids and terpenoids, has great potential for development and it is worthy of further exploration by domestic and foreign scholars. In this paper, the research status of active constituents of traditional Chinese medicine with inhibition of complement system is reviewed, and the application prospect of natural active ingredients inhibiting complement system is analyzed, so as to provide scientific research ideas and methods for further research on complement inhibitors.
引文
[1]RicklinD,Hajishengallis G,Yang K,et al.Complement:a key system for immune surveillance and homeostasis[J].Nat Immunol,2010,11(9):785-797.
[2]于蓝,张继瑜,牛建荣,等.中草药在免疫调节中的应用前景[J].中兽医医药杂志,2010,29(1):73-75.
[3]杨柳,谢红浪.补体相关性肾病[J].肾脏病与透析肾移植杂志,2014,23(5):482-485.
[4]崔敏.补体抑制剂及其在肾脏疾病治疗中的应用[J].肾脏病与透析肾移植杂志,2003,12(6):568-578.
[5]徐小娜,陈亮宇,赵心清.天然抗补体活性物质研究进展[J].天然产物研究与开发,2015,27(2):355-359.
[6]徐晗,章蕴毅,张建文,等.天然产物中的抗补体活性成分[J].中国天然药物,2007,5(5):322-332.
[7]Makridea SC.Therapeutic inhibition of the complement system[J].Pharmacol Rev,1998,50(1):59-87.
[8]曾敏,徐惠芳.云木香多糖的抗补体活性研究[J].现代中药研究与实践,2018,32(2):23-26.
[9]张庆,雷林生,林勤保,等.大枣多糖体外抗补体活性及促进小鼠脾细胞的增殖作用[J].中药药理与临床,1998,14(5):20-22.
[10]杨涛,郭龙,李灿,等.红芪多糖HPS1-D的化学结构和抗补体活性研究[J].中国中药杂志,2014,39(1):89-93.
[11]Masashi T,Keiko M,Noriko S,et al.Characterization of two novel polysaccharides having immunological activities from the root of Panax Ginseng[J].Biol Pharm Bull,1993,16(11):1087-1090.
[12]杨涛,陈平.珠子参多糖结构的初步表征和抗补体活性研究[J].武汉轻工大学学报,2016,35(1):26-29.
[13]朱燕梅,黄玉珊,王秋林.银杏叶制剂在心血管疾病中的应用进展[J].江西中医药,2015,4(46):64-67.
[14]Ishimi Y,Takano F,Yamauchi J,et al.Study on food labeling andthe content of soybean isoflavones in health foods[J].Jpn J Nutr Diet,2009,67(2):49-57.
[15]阮姝楠,卢燕,陈道峰.广藿香的抗补体活性成分[J].中国中药杂志,2013,38(13):2129-2135.
[16]何常明,陈道峰.苦参和山豆根黄酮类成分及其生物活性的比较研究[A].中国植物学会药用植物及植物药专业委员会.第九届全国药用植物及植物药学术研讨会论文集[C].中国植物学会药用植物及植物药专业委员会:中国植物学会,2010:1.
[17]姚士,徐乃玉,褚纯隽,等.蓝萼香茶菜的抗补体活性成分研究[J].中国中药杂志,2013,38(2):199-203.
[18]麦明朗,余林中,刘俊珊.“中药抗生素”鱼腥草抗炎作用研究及临床应用进展[J].中药药理与临床,2018,34(5):172-176.
[19]吴彦,魏和平,王建波.半枝莲多糖B3-PS2分离纯化及抗补体活性研究[J].药学学报,2009,44(6):615-619.
[20]褚纯隽,李显伦,夏龙,等.乌饭树叶的抗补体活性成分研究[J].中草药,2014,45(4):458-465.
[21]周捷,章蕴毅,张建文,等.中药杜仲对补体系统的作用[J].复旦学报(医学版),2006,3(1):101-106.
[22]葛继荣,王和鸣,杨连梓,等.复方杜仲健骨颗粒治疗膝关节骨性关节炎Ⅱ期临床试验总结[J].中国中医骨伤科杂志,2002,10(5):19-23.
[23]Lee IS,Oh SR,Jung KY,et al.Anticomplementary activity and complete^13 C-NMR assignment of citrostadienol from Schizandra chinensis[J].Pharmace Bio,1997,35(5):358.
[24]Ling M,Diddlesden SJ,Morgan BP,et al.A component of the medicinal herb ephedra blocks activation in the classical and alternative pathways of complement[J].Clin Exp Immunol,1995,102(3):582-588.
[25]吕诚,胡小令,杨宝林,等.雷公藤内酯醇对大鼠大脑皮质内注射β-淀粉样蛋白后补体C1q和C3表达的影响[J].中国老年学杂志,2011,31(5):800-803.
[26]倪付勇,刘露,宋亚玲,等.金银花中抗补体活性酚酸类成分的研究[J].中国中药杂志,2015,40(2):269-274.
[27]侯灵莉,李松林,闫银萍,等.香椿果抗补体活性成分[J].中国实验方剂学杂志,2017,23(21):52-58.
[28]杨庆雄,张万全,余天华,等.玫瑰花中抗补体活性成分研究[J].安徽农业科学,2011,39(26):15 962-15 964.
[29]Skattum L,van Deuren M,van der Poll T,et al.Complement deficiency states and associated infections[J].Mol Immunol,2011,48(14):1643-1655.
[30]Degn SE,Jensenius JC,Thiel S.Disease-causing mutations in genes of the complement system[J].Am J Hum Genet,2011,88(6):689-705.
[31]Ermini L,Goodship TH,Strain L,et al.Common genetic variants in complement genes other than CFH,CD46,and the CFHRs are not associated with aHUS[J].Mol Immunol,2012,49(4):640-648.
[32]Sturfelt G,Truedsson L.Complement and its breakdown products in SLE[J].Rheumatology(Oxford),2005,44(10):1227-1232.
[33]Boschetti C,Fermo E,Bianchi P,et al.Clinical and molecular aspects of 23 patients affected by paroxysmal nocturnal[J].Am J Hematol,2004,77(1):36-44.
[34]Derek H,Marcus S.An update on hereditary angioedema[J].Curr Opin Pediatr,2012,24(5):638-646.
[35]Reynolds R,Hartnett ME,Atkinson JP,et al.Plasma complement components and a activation fragments:associations with age-related macular degeneration genotypes and phenotypes[J].Invest Ophthalmol Vis Sci,2009,50(12):5818-5827.
[36]肖慧捷,何瑞娟.补体系统调控异常与C3肾小球病[J].北京大学学报(医学版),2013,45(2):323-326.
[37]喻小娟,刘刚,赵明辉.12例C3肾小球肾炎的临床病理特点及其血浆补体活化成分分析[J].中国肾脏病杂志,2011,27(11):797-801.
[38]李敏,孙黔云,赵琼,等.补体旁路过度激活影响体内凝血功能[J].中国药理学通报,2014,30(1):39-44.
[39]Holz FG,Sadda SR,Busbee B,et al.Efficacy and safety of lampalizumab for atrophy due to age-related macular degeneration:chroma and spectri phase 3 randomized clinical trials[J].JAMA Ophthalmol,2018,136(6):666-677.
[40]Raghunathan V,Sethi SK,Dragon-Durey MA,et al.Targeting renin-angiotensin system in malignant hypertension in atypita hemolytic uremic syndrome[J].Indian J Nephrol,2017,27(2):136-140.
[2]于蓝,张继瑜,牛建荣,等.中草药在免疫调节中的应用前景[J].中兽医医药杂志,2010,29(1):73-75.
[3]杨柳,谢红浪.补体相关性肾病[J].肾脏病与透析肾移植杂志,2014,23(5):482-485.
[4]崔敏.补体抑制剂及其在肾脏疾病治疗中的应用[J].肾脏病与透析肾移植杂志,2003,12(6):568-578.
[5]徐小娜,陈亮宇,赵心清.天然抗补体活性物质研究进展[J].天然产物研究与开发,2015,27(2):355-359.
[6]徐晗,章蕴毅,张建文,等.天然产物中的抗补体活性成分[J].中国天然药物,2007,5(5):322-332.
[7]Makridea SC.Therapeutic inhibition of the complement system[J].Pharmacol Rev,1998,50(1):59-87.
[8]曾敏,徐惠芳.云木香多糖的抗补体活性研究[J].现代中药研究与实践,2018,32(2):23-26.
[9]张庆,雷林生,林勤保,等.大枣多糖体外抗补体活性及促进小鼠脾细胞的增殖作用[J].中药药理与临床,1998,14(5):20-22.
[10]杨涛,郭龙,李灿,等.红芪多糖HPS1-D的化学结构和抗补体活性研究[J].中国中药杂志,2014,39(1):89-93.
[11]Masashi T,Keiko M,Noriko S,et al.Characterization of two novel polysaccharides having immunological activities from the root of Panax Ginseng[J].Biol Pharm Bull,1993,16(11):1087-1090.
[12]杨涛,陈平.珠子参多糖结构的初步表征和抗补体活性研究[J].武汉轻工大学学报,2016,35(1):26-29.
[13]朱燕梅,黄玉珊,王秋林.银杏叶制剂在心血管疾病中的应用进展[J].江西中医药,2015,4(46):64-67.
[14]Ishimi Y,Takano F,Yamauchi J,et al.Study on food labeling andthe content of soybean isoflavones in health foods[J].Jpn J Nutr Diet,2009,67(2):49-57.
[15]阮姝楠,卢燕,陈道峰.广藿香的抗补体活性成分[J].中国中药杂志,2013,38(13):2129-2135.
[16]何常明,陈道峰.苦参和山豆根黄酮类成分及其生物活性的比较研究[A].中国植物学会药用植物及植物药专业委员会.第九届全国药用植物及植物药学术研讨会论文集[C].中国植物学会药用植物及植物药专业委员会:中国植物学会,2010:1.
[17]姚士,徐乃玉,褚纯隽,等.蓝萼香茶菜的抗补体活性成分研究[J].中国中药杂志,2013,38(2):199-203.
[18]麦明朗,余林中,刘俊珊.“中药抗生素”鱼腥草抗炎作用研究及临床应用进展[J].中药药理与临床,2018,34(5):172-176.
[19]吴彦,魏和平,王建波.半枝莲多糖B3-PS2分离纯化及抗补体活性研究[J].药学学报,2009,44(6):615-619.
[20]褚纯隽,李显伦,夏龙,等.乌饭树叶的抗补体活性成分研究[J].中草药,2014,45(4):458-465.
[21]周捷,章蕴毅,张建文,等.中药杜仲对补体系统的作用[J].复旦学报(医学版),2006,3(1):101-106.
[22]葛继荣,王和鸣,杨连梓,等.复方杜仲健骨颗粒治疗膝关节骨性关节炎Ⅱ期临床试验总结[J].中国中医骨伤科杂志,2002,10(5):19-23.
[23]Lee IS,Oh SR,Jung KY,et al.Anticomplementary activity and complete^13 C-NMR assignment of citrostadienol from Schizandra chinensis[J].Pharmace Bio,1997,35(5):358.
[24]Ling M,Diddlesden SJ,Morgan BP,et al.A component of the medicinal herb ephedra blocks activation in the classical and alternative pathways of complement[J].Clin Exp Immunol,1995,102(3):582-588.
[25]吕诚,胡小令,杨宝林,等.雷公藤内酯醇对大鼠大脑皮质内注射β-淀粉样蛋白后补体C1q和C3表达的影响[J].中国老年学杂志,2011,31(5):800-803.
[26]倪付勇,刘露,宋亚玲,等.金银花中抗补体活性酚酸类成分的研究[J].中国中药杂志,2015,40(2):269-274.
[27]侯灵莉,李松林,闫银萍,等.香椿果抗补体活性成分[J].中国实验方剂学杂志,2017,23(21):52-58.
[28]杨庆雄,张万全,余天华,等.玫瑰花中抗补体活性成分研究[J].安徽农业科学,2011,39(26):15 962-15 964.
[29]Skattum L,van Deuren M,van der Poll T,et al.Complement deficiency states and associated infections[J].Mol Immunol,2011,48(14):1643-1655.
[30]Degn SE,Jensenius JC,Thiel S.Disease-causing mutations in genes of the complement system[J].Am J Hum Genet,2011,88(6):689-705.
[31]Ermini L,Goodship TH,Strain L,et al.Common genetic variants in complement genes other than CFH,CD46,and the CFHRs are not associated with aHUS[J].Mol Immunol,2012,49(4):640-648.
[32]Sturfelt G,Truedsson L.Complement and its breakdown products in SLE[J].Rheumatology(Oxford),2005,44(10):1227-1232.
[33]Boschetti C,Fermo E,Bianchi P,et al.Clinical and molecular aspects of 23 patients affected by paroxysmal nocturnal[J].Am J Hematol,2004,77(1):36-44.
[34]Derek H,Marcus S.An update on hereditary angioedema[J].Curr Opin Pediatr,2012,24(5):638-646.
[35]Reynolds R,Hartnett ME,Atkinson JP,et al.Plasma complement components and a activation fragments:associations with age-related macular degeneration genotypes and phenotypes[J].Invest Ophthalmol Vis Sci,2009,50(12):5818-5827.
[36]肖慧捷,何瑞娟.补体系统调控异常与C3肾小球病[J].北京大学学报(医学版),2013,45(2):323-326.
[37]喻小娟,刘刚,赵明辉.12例C3肾小球肾炎的临床病理特点及其血浆补体活化成分分析[J].中国肾脏病杂志,2011,27(11):797-801.
[38]李敏,孙黔云,赵琼,等.补体旁路过度激活影响体内凝血功能[J].中国药理学通报,2014,30(1):39-44.
[39]Holz FG,Sadda SR,Busbee B,et al.Efficacy and safety of lampalizumab for atrophy due to age-related macular degeneration:chroma and spectri phase 3 randomized clinical trials[J].JAMA Ophthalmol,2018,136(6):666-677.
[40]Raghunathan V,Sethi SK,Dragon-Durey MA,et al.Targeting renin-angiotensin system in malignant hypertension in atypita hemolytic uremic syndrome[J].Indian J Nephrol,2017,27(2):136-140.